OCUL

Ocular Therapeutix, Inc. [OCUL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OCUL Stock Summary

Top 10 Correlated Stocks

OCUL


In the News

08:00 30 Nov 2023 OCUL

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences:

10:32 30 Nov 2023 OCUL

Ocular Therapeutix, Inc. (OCUL) Q3 2023 Earnings Call Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President and CEO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Peter Kaiser - Chief Medical Advisor, Retina Conference Call Participants Jon Wolleben - JMP Yi Chen - H.C. Wainwright Operator Good day.

10:33 30 Nov 2023 OCUL

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

08:00 30 Nov 2023 OCUL

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a panel at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at 11:00 AM EDT.

08:24 30 Nov 2023 OCUL

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.28 per share a year ago.

04:01 30 Nov 2023 OCUL

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that 12-month data from the U.S.-based Phase 1 trial evaluating OTX-TKI for the treatment of wet AMD will be presented at the 2023 Clinical Trials at the Summit Annual Meeting being held on June 10th in Park City, Utah. The Company will also participate in a panel discussing the challenges of bringing novel treatments to the market. Ocular Therapeutix is also sponsoring a presentation discussing the Company's proprietary bioresorbable hydrogel-based formulation technology and retina focused clinical programs. A conference call discussing the 12-month data from the U.S.-based Phase 1 clinical trial of OTX-TKI presented at the Clinical Trials at the Summit will be hosted by the Ocular Therapeutix management team on Monday, June 12th at 8:30 AM ET.

08:00 30 Nov 2023 OCUL

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference

BEDFORD, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023 at 12:30 PM EDT at the Marriott Marquis in New York, NY.

09:00 30 Nov 2023 OCUL

Ocular Therapeutix, Inc. (OCUL) Q1 2023 Earnings Call Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Rabia Ozden - Chief Medical Officer Steve Meyers - Senior Vice President of Commercial Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Tara Bancroft - Cowen Colleen Kusy - Baird Yi Chen - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by.

07:45 30 Nov 2023 OCUL

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.

08:00 30 Nov 2023 OCUL

Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference

BEDFORD, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:00 PM EDT at the New York Hilton Midtown in New York, NY.

OCUL Financial details

Company Rating
Neutral
Market Cap
177.9M
Income
-69.32M
Revenue
57.59M
Book val./share
0.1
Cash/share
1.39
Dividend
-
Dividend %
-
Employees
274
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
-2.62
Forward P/E
-2.52
PEG
-0.05
P/S
3.16
P/B
23.15
P/C
1.85
P/FCF
-2.51
Quick Ratio
3.83
Current Ratio
4.03
Debt / Equity
10.57
LT Debt / Equity
10.33
-
-
EPS (TTM)
-0.89
EPS next Y
-1.02
EPS next Q
-0.25
EPS this Y
492.86%
EPS next Y
15.06%
EPS next 5Y
-23.48%
EPS last 5Y
-11.28%
Revenue last 5Y
91.68%
Revenue Q/Q
-1.55%
EPS Q/Q
-97.5%
-
-
-
-
SMA20
-33.33%
SMA50
-50%
SMA100
-60%
Inst Own
38.92%
Inst Trans
0.7%
ROA
-43%
ROE
-495%
ROC
-0.64%
Gross Margin
91%
Oper. Margin
-142%
Profit Margin
-120%
Payout
-
Shs Outstand
79.42M
Shs Float
70.05M
-
-
-
-
Target Price
10
52W Range
1.995-7.96
52W High
-63.21%
52W Low
+157.5%
RSI
46
Rel Volume
1.7
Avg Volume
785.03K
Volume
1.33M
Perf Week
9.57%
Perf Month
8.42%
Perf Quarter
-65.34%
Perf Half Y
-59.7%
-
-
-
-
Beta
1.184
-
-
Volatility
0.12%, 0.33%
Prev Close
12.45%
Price
2.575
Change
15.99%

OCUL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.050.090.290.570.67
Net income per share
-1.51-1.99-2.63-0.14-0.83
Operating cash flow per share
-1.29-1.71-0.88-0.86-0.78
Free cash flow per share
-1.34-1.76-0.9-0.87-0.82
Cash per share
1.421.23.752.151.33
Book value per share
0.94-0.081.251.150.46
Tangible book value per share
0.94-0.081.251.150.46
Share holders equity per share
0.94-0.081.251.150.46
Interest debt per share
0.71.451.070.860.93
Market cap
151.7M178.83M1.26B532.46M216.02M
Enterprise value
122.42M183.74M1.09B427.28M178M
P/E ratio
-2.63-1.99-7.88-49.28-3.41
Price to sales ratio
76.2342.3172.2612.234.2
POCF ratio
-3.08-2.31-23.48-8.12-3.62
PFCF ratio
-2.97-2.24-23.12-7.98-3.41
P/B Ratio
4.23-49.2616.536.056.11
PTB ratio
4.23-49.2616.536.056.11
EV to sales
61.5243.4762.529.823.46
Enterprise value over EBITDA
-2.1-2.17-17.36-5.48-2.29
EV to operating cash flow
-2.49-2.37-20.32-6.52-2.99
EV to free cash flow
-2.4-2.3-20-6.4-2.81
Earnings yield
-0.38-0.5-0.13-0.02-0.29
Free cash flow yield
-0.34-0.45-0.04-0.13-0.29
Debt to equity
0.69-16.350.770.671.82
Debt to assets
0.340.750.220.290.43
Net debt to EBITDA
0.5-0.062.711.350.49
Current ratio
6.1459.237.264.13
Interest coverage
-34-14.06-9.29-11.7-11.2
Income quality
0.820.90.34100.84
Dividend Yield
00000
Payout ratio
-0.0100-0.070
Sales general and administrative to revenue
9.445.231.310.730.63
Research and developement to revenue
18.559.721.651.151.04
Intangibles to total assets
00000
Capex to operating cash flow
0.040.030.020.020.06
Capex to revenue
-0.95-0.53-0.05-0.03-0.07
Capex to depreciation
-0.83-0.88-0.3-0.49-1.76
Stock based compensation to revenue
3.762.070.430.340.33
Graham number
5.661.898.611.912.92
ROIC
-0.94-1.36-0.45-0.83-0.64
Return on tangible assets
-0.79-1.14-0.61-0.05-0.42
Graham Net
0.45-0.560.860.830.07
Working capital
47.03M48.14M219.5M164.96M98.23M
Tangible asset value
35.88M-3.63M76.1M88M35.38M
Net current asset value
19.03M-22.2M60.39M74.41M15.72M
Invested capital
0.69-16.350.770.671.82
Average receivables
213.5K1.37M7.4M16.69M21.23M
Average payables
3.27M3.12M2.99M3.65M4.86M
Average inventory
169.5K585.5K1.08M1.23M1.61M
Days sales outstanding
36.87220.02256.97177.25151.16
Days payables outstanding
2.33K513.04474.69380.41411.87
Days of inventory on hand
170.33149.77210.45103.55158.7
Receivables turnover
9.91.661.422.062.41
Payables turnover
0.160.710.770.960.89
Inventory turnover
2.142.441.733.522.3
ROE
-1.6124.78-2.1-0.12-1.79
Capex per share
-0.05-0.05-0.01-0.02-0.05

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.160.180.170.190.19
Net income per share
-0.35-0.15-0.47-0.26-0.01
Operating cash flow per share
-0.17-0.22-0.26-0.26-0.1
Free cash flow per share
-0.18-0.25-0.3-0.28-0.1
Cash per share
1.571.331.020.851.39
Book value per share
0.60.460.130.040.1
Tangible book value per share
0.60.460.130.040.1
Share holders equity per share
0.60.460.130.040.1
Interest debt per share
0.80.860.860.861
Market cap
319.45M216.4M407.83M402.73M249.23M
Enterprise value
258.2M178.38M393.41M400.89M221.7M
P/E ratio
-2.98-4.61-2.8-4.87-120.75
Price to sales ratio
26.715.3730.4926.5216.67
POCF ratio
-24.26-12.76-20.42-20.06-32.23
PFCF ratio
-22.88-11.33-17.46-18.25-31.19
P/B Ratio
6.916.1242130.4631.74
PTB ratio
6.916.1242130.4631.74
EV to sales
21.5812.6729.4226.414.83
Enterprise value over EBITDA
-12.44-9.42-17.89-20.91-11.54
EV to operating cash flow
-19.61-10.52-19.7-19.97-28.67
EV to free cash flow
-18.49-9.34-16.85-18.17-27.74
Earnings yield
-0.08-0.05-0.09-0.050
Free cash flow yield
-0.04-0.09-0.06-0.05-0.03
Debt to equity
1.291.826.6520.9810.57
Debt to assets
0.380.430.50.530.51
Net debt to EBITDA
2.952.010.660.11.43
Current ratio
4.984.133.613.114.03
Interest coverage
-11.99-10.48-12.75-10.335.61
Income quality
0.541.090.660.9714.98
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.710.590.680.540.57
Research and developement to revenue
1.150.961.10.991
Intangibles to total assets
00000
Capex to operating cash flow
0.060.130.170.10.03
Capex to revenue
-0.07-0.15-0.25-0.13-0.02
Capex to depreciation
-1.56-4.38-7-3.05-0.29
Stock based compensation to revenue
0.350.30.340.290.3
Graham number
2.171.251.150.490.12
ROIC
-0.21-0.13-0.32-0.290.14
Return on tangible assets
-0.17-0.08-0.28-0.170
Graham Net
0.310.07-0.3-0.4-0.32
Working capital
116.35M98.23M77.45M68.36M106.19M
Tangible asset value
46.23M35.38M9.71M3.09M7.85M
Net current asset value
33.27M15.72M-11.7M-18.76M-13.27M
Invested capital
1.291.826.6520.9810.57
Average receivables
20.14M20.56M21.22M24.22M25.45M
Average payables
4.51M5.22M5.28M4.51M3.78M
Average inventory
1.52M1.76M2.12M2.24M2.23M
Days sales outstanding
148.95136.35142.15161.85142.01
Days payables outstanding
445.22455.15403.37246.53260.39
Days of inventory on hand
129.59175.38167.99152.12147.52
Receivables turnover
0.60.660.630.560.63
Payables turnover
0.20.20.220.370.35
Inventory turnover
0.690.510.540.590.61
ROE
-0.58-0.33-3.75-6.7-0.07
Capex per share
-0.01-0.03-0.04-0.030

OCUL Frequently Asked Questions

What is Ocular Therapeutix, Inc. stock symbol ?

Ocular Therapeutix, Inc. is a US stock , located in Bedford of Ma and trading under the symbol OCUL

Is Ocular Therapeutix, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10

What is OCUL stock prediction ?

What is Ocular Therapeutix, Inc. stock quote today ?

Ocular Therapeutix, Inc. stock price is $2.575 today.

Is Ocular Therapeutix, Inc. stock public?

Yes, Ocular Therapeutix, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap